MICHAEL HARGROVE: Open Payments
NPI 1336114115 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,898 in 65 payments from 10 companies in 2025. Trend: 2023 $2,537 · 2024 $8,702 · 2025 $1,898
Food & beverage: $1,898
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $568 |
| Axsome Therapeutics, Inc. | 20 | $463 |
| Janssen Pharmaceuticals, Inc | 4 | $209 |
| ABBVIE INC. | 10 | $195 |
| E.R. Squibb & Sons, L.L.C. | 7 | $154 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Neurocrine BioSciences, Inc. | 3 | $83 |
| Lundbeck LLC | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: Auvelity, FANAPT, INVEGA SUSTENNA, VRAYLAR, HETLIOZ, COBENFY, REXULTI, INGREZZA.
Industry payments across NY — which companies pay providers there.
